



DELcore

**100+**  
Licensed  
Programs

**> 50**  
Trusted  
Partners

Check our track  
record:



## Exclusive Discovery Partnership Tailored to Your Success

DELcore offers an unparalleled premium, exclusive partnership that drives rapid, high-impact drug discovery. Partners access X-Chem's most expansive DNA-encoded libraries (DEL)—over 225 billion molecules of proprietary chemistries designed for hit identification.

As a DELcore partner, you have the unique opportunity to own the exclusive rights to the active compounds identified during the discovery process. This gives you the ability to develop these compounds as part of your own portfolio, ensuring full control over your discoveries and future therapeutic development.

### Key Benefits



#### Exclusive Licensing Rights

Target-based exclusivity and choice of license to confirmed hit compounds, enabling partners to build and control their portfolio.



#### Tailored Strategy

Personalized support and customized discovery campaigns designed to align with partners' therapeutic goals.



#### End-to-end Support

Expert guidance from X-Chem scientists from reagent design, generation, qualification, to hit-to-lead\* and lead optimization\*.



#### Comprehensive Libraries

Access diverse pharmacophores and scaffolds, including macrocycles, all optimized for drug-like properties.




#### Detailed SAR Analysis & Mechanistic Insights

Learn about binding modes, target engagement, and pathway modulation to drive informed decision on compound selection

\* Add-on support

## Win From the Start: Access Expansive, Diverse Libraries for Better Drug-like Hits

Under the DELcore partnership model, partners can choose between covalent or non-covalent hit discovery. Our reversible (non-covalent) libraries are synthesized using proprietary chemistries and have contributed to over 100 drug discovery licenses. Meanwhile, our irreversible libraries feature clinically validated, FDA-approved electrophiles, designed to de-risk covalent drug liabilities and enhance the safety profile of your compounds.



## DELcore vs. DELflex: Which Suits You?

Feature	DELflex	DELcore
<b>Library Access</b>	> 15 billion non-covalent compounds > 115 billion covalent compounds	> 125 billion non-covalent compounds > 100 billion covalent compounds
<b>License Rights</b>	No exclusive license ownership; may file IP application	Option to license hit compounds as part of partner's proprietary portfolio; may file IP application
<b>Exclusivity</b>	Open access; no target exclusivity	Target-based exclusivity for the duration of the project; compound-based exclusivity upon license
<b>Cost Flexibility</b>	Cost-effective, scalable solution for rapid screening	Premium partnership with comprehensive support and the ability to license compounds

**X-Chem is the partner you need to unlock exponential possibilities in your small molecule drug discovery.**

**Find Your Next Candidate With X-Chem**

### ABOUT X-CHEM

X-Chem, Inc. is the leader in small molecule discovery science, providing pharmaceutical and biotech companies a complete, seamless solution for screening, hit validation and lead optimization. As pioneers of DNA-encoded chemical library (DEL) technology, the company leverages its market-leading DEL platform to discover novel small molecule leads against challenging, high-value therapeutic targets. In-house lead optimization services enable clients to progress their compounds directly for even higher quality outputs. Our expertise in medicinal chemistry, custom synthesis and scale-up process chemistry enables us to support all aspects of drug discovery, supporting lead optimization through candidate identification.